Who is sponsoring NCT03442101?

NCT03442101 is sponsored by University of Alabama at Birmingham.

Is NCT03442101 still recruiting?

NCT03442101 is currently active, enrolled. Last updated 12 January 2026.

Last reviewed 2026-01-12 · How we verify

NCT03442101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

Active, enrolled Last updated 12 January 2026

What this trial tests

trial testing Patients with psychosis will be treated with known antipsychotic medication in Psychosis in 156 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 April 2018

Primary endpoint
30 December 2026

31 December 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	156
Start date	1 April 2018
Primary completion	30 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Patients with psychosis will be treated with known antipsychotic medication — full drug profile →

Conditions studied

Psychosis — all drugs for Psychosis →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 17 to 35, any sex, with Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis.
Maximo JO, Nelson EA, Armstrong WP, Kraguljac NV, et al · · 2020 · cited 33× · PMID 31902581 · DOI 10.1016/j.bpsc.2019.10.014
Salience network glutamate and brain connectivity in medication-naïve first episode patients - A multimodal magnetic resonance spectroscopy and resting state functional connectivity MRI study.
Maximo JO, Briend F, Armstrong WP, Kraguljac NV, et al · · 2021 · cited 24× · PMID 34662778 · DOI 10.1016/j.nicl.2021.102845
Neurite Orientation Dispersion and Density Imaging (NODDI) and Duration of Untreated Psychosis in Antipsychotic Medication-Naïve First Episode Psychosis Patients.
Kraguljac NV, Monroe WS, Anthony T, Jindal RD, et al · · 2021 · cited 10× · PMID 36969709 · DOI 10.1016/j.ynirp.2021.100005
Higher-order functional brain networks and anterior cingulate glutamate + glutamine (Glx) in antipsychotic-naïve first episode psychosis patients.
Maximo JO, Briend F, Armstrong WP, Kraguljac NV, et al · · 2024 · cited 7× · PMID 38600117 · DOI 10.1038/s41398-024-02854-7
Topological Perturbations in the Functional Connectome Support the Deficit/Non-deficit Distinction in Antipsychotic Medication-Naïve First Episode Psychosis Patients.
Teles M, Maximo JO, Lahti AC, Kraguljac NV. · · 2024 · cited 5× · PMID 38666705 · DOI 10.1093/schbul/sbae054
White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-Naïve First-Episode Psychosis Patients.
Bryant JE, Lahti AC, Briend F, Kraguljac NV. · · 2021 · cited 5× · PMID 33693906 · DOI 10.1093/schbul/sbab014
A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naïve first episode psychosis patients.
Nelson EA, Kraguljac NV, Bashir A, Cofield SS, et al · · 2025 · cited 4× · PMID 39580605 · DOI 10.1038/s41380-024-02812-1
Higher-Order Intrinsic Brain Network Trajectories After Antipsychotic Treatment in Medication-Naïve Patients With First-Episode Psychosis.
Maximo JO, Armstrong WP, Kraguljac NV, Lahti AC. · · 2024 · cited 4× · PMID 38272288 · DOI 10.1016/j.biopsych.2024.01.010

Verify or expand the search:

Other recruiting trials for Psychosis

Currently open trials in the same condition.

NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
NCT07196462 — Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia · NA · recruiting
NCT07364825 — Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03442101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03442101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing